Vancouver’s AbCellera has acquired Trianni in an all-cash transaction valued at US $90 million.
Trianni’s genetic engineering technology is a platform for developing humanized mice. The acquisition deepens AbCellera’s technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties.
“Trianni marks our fourth and largest strategic technology addition to date. With its technology and team, Trianni amplifies our capability to generate human antibodies and provides a strong foundation for developing increasingly powerful transgenic mouse technologies,” said Carl Hansen, Ph.D., CEO of AbCellera.
AbCellera is currently hiring in Vancouver and will be participating in the Tech Talent Canada virtual job fair on November 25th.
“Trianni adds a key pillar to our platform, which now includes genetically engineered rodents, microfluidic single-cell screening, repertoire sequencing, AI-powered computation, and bispecific protein engineering. By integrating these technologies, we aim to provide our partners with access to a modern operating system that improves the speed and probability of success of antibody drug development.”
The flagship Trianni Mouse® was designed to maximize immune responses, increase antibody diversity, and preserve natural maturation of fully human antibodies in rodents. The Trianni Mouse is also a core platform that supports the rapid development of new mouse strains tailored to address the most challenging antibody discovery programs.